Lytix Biopharma is a private clinical stage company developing a topical antimicrobial peptide and a powerful Oncolytic Peptide Immunotherapy (OPI).

Lytix Biopharma – oncolytic peptide immunotherapy

Lytix Biopharma’s technology is based on nature’s own defense mechanism: the membranes of bacteria and cancer cells are destroyed. Its patented technology has the potential to meet two substantial medical challenges: cancer therapy that increases patient specific immune response to cancer and treatment of infections regardless of resistance. Lytix Biopharma’s strategy is to develop its drug candidates through Phase II, and then collaborate with partners for the final stages of product development and commercialization. Lytix Biopharma’s drug candidate LTX-315 is a powerful Oncolytic Peptide Immunotherapy (OPI) inducing a potent stimulation of an extended range of tumour specific T-cells attacking cancer – increasing patient specific immune response. LTX-315 is an ideal combinations partner for immune checkpoint inhibitors (ICIs), augmenting efficacy without adding toxicity.

Lytix Biopharma also develops LTX-109, a topical antimicrobial peptide. This drug candidate is in Phase I/II development for the treatment of mild Diabetic Foot Infections (DFI). There are no approved topical anti-infective therapies for the treatment of mild DFI today, and the medical experts express there is a high unmet need for a topical anti-infective alternative. LTX-109 uses a novel membrane lysing mode of action that causes selective, rapid membrane disruption. Furthermore, LTX-109 has a good efficacy against antibiotic-resistant species and a broad spectrum of activity, including a high activity against biofilm infection.

Lytix Biopharma is headquartered in Tromsø and Oslo (Norway). Management Team is composed by Unni Hjelmaas, Andrew Saunders, Wenche Marie Olsen, Øystein Rekdal, John Svendsen, Håkan Wickholm and Kjetil Vangsnes. Board of Directors is composed by Gert Munthe, Knut Eidissen, John Sigurd Svendsen, Kari Grønås, Morten Jurs, Lena Torlegård and Debasish Roychowdhury. In addition to equity financing the company has qualified to substantial funding from public grants. Following successful Phase II results, Lytix Biopharma will seek partnerships with industry majors for late stage development and commercialization. And IPO/ stock exchange listing is under consideration.

More about Lytix Biopharma : www.lytixbiopharma.com

Lytix Biopharma – Lytix – topical antimicrobial peptide – Oncolytic Peptide Immunotherapy – OPI – LTX-315 – LTX-109 – immune checkpoint inhibitor – Diabetic Foot Infections – DFI – Diabetic Foot Infection – biofilm infection

Lytix Biopharma – Lytix – topical antimicrobial peptide – Oncolytic Peptide Immunotherapy – OPI – LTX-315 – LTX-109 – immune checkpoint inhibitor – Diabetic Foot Infections – DFI – Diabetic Foot Infection – biofilm infection – LTX315 – LTX109